诺和诺德公司针对转甲状腺素蛋白淀粉样变性心肌病（ATTR-CM）开展的Coramitug三期临床试验，预计将于2029年完成最终研究。该试验是诺和诺德与生物技术公司Prothena Corporation plc合作推进的重要项目，旨在评估候选药物对ATTR-CM患者的疗效与安全性。
ATTR-CM作为一种进行性、致命性的罕见疾病，目前治疗选择有限。Coramitug作为一款备受关注的在研疗法，其三期临床试验的推进将为该疾病领域带来新的希望。整个研究周期跨度较长，反映了对罕见病药物开发科学严谨性的高度重视。
这项跨国研究的最终完成节点设定在2029年，标志着ATTR-CM治疗领域可能迎来重要突破。随着试验的逐步推进，后续数据披露将成为行业关注焦点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.